Maria Montes de Oca1, Carlos Tálamo2, Ronald J Halbert3, Rogelio Perez-Padilla4, Maria Victorina Lopez5, Adriana Muiño5, José Roberto B Jardim6, Gonzalo Valdivia7, Julio Pertuzé8, Dolores Moreno2, Ana Maria B Menezes9. 1. Servicio de Neumonología, Hospital Universitario de Caracas, Facultad de Medicina, Universidad Central de Venezuela, Caracas, Venezuela. Electronic address: mmdeoca@cantv.net. 2. Servicio de Neumonología, Hospital Universitario de Caracas, Facultad de Medicina, Universidad Central de Venezuela, Caracas, Venezuela. 3. UCLA School of Public Health, Los Angeles, CA. 4. Institute of Respiratory Diseases, Mexico City, Mexico. 5. Facultad de Medicina, Universidad de la República, Hospital Maciel, Montevideo, Uruguay. 6. Federal University of São Paulo, Sâo Paulo, Brazil. 7. Departamento de Salud Publica, Facultad de Medicina, Pontifícia Universidad Católica de Chile, Santiago de Chile, Chile. 8. Catedra de Neumologia, Facultad de Medicina, Pontifícia Universidad Católica de Chile, Santiago de Chile, Chile. 9. Faculdade de Medicina, Universidade Federal de Pelotas, Pelotas, RS, Brazil.
Abstract
BACKGROUND: Recurrent exacerbations are common in COPD patients. Limited information exists regarding exacerbation frequency in COPD patients from epidemiologic studies. We examined the frequency of self-reported exacerbations and the factors influencing exacerbation frequency among COPD patients in a population-based study conducted in Latin America. METHODS: We used a post-bronchodilator FEV(1)/FVC ratio of < 0.70 to define COPD. Exacerbation was self-reported and defined by symptoms (deterioration of breathing symptoms that affected usual daily activities or caused missed work). RESULTS: Spirometry was performed in 5,314 subjects. There were 759 subjects with airflow limitation; of these, 18.2% reported ever having had an exacerbation, 7.9% reported having an exacerbation, and 6.2% reported having an exacerbation requiring at least a doctor visit within the past year. The proportion of individuals with an exacerbation significantly increased by Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages, from 4.2% in stage 1 to 28.9% in stages 3 and 4. The self-reported exacerbation rate was 0.58 exacerbations per year. The rate of exacerbations requiring at least a doctor visit and length of stay in hospital due to exacerbations also increased as COPD severity progressed. The factors associated with having an exacerbation in the past year were dyspnea, prior asthma diagnosis, receiving any respiratory therapy, and disease severity of GOLD stages 3 and 4. CONCLUSIONS: The proportion of individuals with airflow limitation and self-reported exacerbation increases as the disease severity progresses. Dyspnea, prior asthma diagnosis, receiving any respiratory therapy, and more severe obstruction were significantly associated with having an exacerbation in the past year.
BACKGROUND: Recurrent exacerbations are common in COPDpatients. Limited information exists regarding exacerbation frequency in COPDpatients from epidemiologic studies. We examined the frequency of self-reported exacerbations and the factors influencing exacerbation frequency among COPDpatients in a population-based study conducted in Latin America. METHODS: We used a post-bronchodilator FEV(1)/FVC ratio of < 0.70 to define COPD. Exacerbation was self-reported and defined by symptoms (deterioration of breathing symptoms that affected usual daily activities or caused missed work). RESULTS: Spirometry was performed in 5,314 subjects. There were 759 subjects with airflow limitation; of these, 18.2% reported ever having had an exacerbation, 7.9% reported having an exacerbation, and 6.2% reported having an exacerbation requiring at least a doctor visit within the past year. The proportion of individuals with an exacerbation significantly increased by Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages, from 4.2% in stage 1 to 28.9% in stages 3 and 4. The self-reported exacerbation rate was 0.58 exacerbations per year. The rate of exacerbations requiring at least a doctor visit and length of stay in hospital due to exacerbations also increased as COPD severity progressed. The factors associated with having an exacerbation in the past year were dyspnea, prior asthma diagnosis, receiving any respiratory therapy, and disease severity of GOLD stages 3 and 4. CONCLUSIONS: The proportion of individuals with airflow limitation and self-reported exacerbation increases as the disease severity progresses. Dyspnea, prior asthma diagnosis, receiving any respiratory therapy, and more severe obstruction were significantly associated with having an exacerbation in the past year.
Authors: Yong Il Hwang; Sang Haak Lee; Jee Hong Yoo; Bock Hyun Jung; Kwang Ha Yoo; Moon Jun Na; Jong Deog Lee; Myung Jae Park; Chi Young Jung; Jae Jeong Shim; Kyung Chan Kim; Yeon Jae Kim; Hye Sook Choi; Ik Su Choi; Choon-Taek Lee; Sang Do Lee; Do Jin Kim; Soo-Taek Uh; Ho Sung Lee; Young Sam Kim; Kwan Ho Lee; Seung Won Ra; Hak Ryul Kim; Soo Jeon Choi; In Won Park; Yong Bum Park; So Young Park; Jaehee Lee; Ki-Suck Jung Journal: J Thorac Dis Date: 2015-12 Impact factor: 2.895
Authors: Maria Montes de Oca; Carlos Aguirre; Maria Victorina Lopez Varela; Maria E Laucho-Contreras; Alejandro Casas; Filip Surmont Journal: Int J Chron Obstruct Pulmon Dis Date: 2016-12-07
Authors: Rogelio Perez-Padilla; Fernando C Wehrmeister; Maria Montes de Oca; Maria Victorina Lopez; Jose R Jardim; Adriana Muiño; Gonzalo Valdivia; Ana Maria B Menezes Journal: Int J Chron Obstruct Pulmon Dis Date: 2018-10-26
Authors: Rogelio Perez-Padilla; Fernando C Wehrmeister; Bartolome R Celli; Maria Victorina Lopez-Varela; Maria Montes de Oca; Adriana Muiño; Carlos Talamo; Jose R Jardim; Gonzalo Valdivia; Carmen Lisboa; Ana Maria B Menezes Journal: PLoS One Date: 2013-08-01 Impact factor: 3.240